連絡電話：(+886) 037-246166 ext. 37727
|1996/09 – 2001/10||Ph.D., Graduate Institute of Life Sciences, National Defense Medical College, Taiwan|
|1993/09 – 1995/06||M.S., Graduate Institute of Immunology, National Taiwan Univ., Taiwan|
|1986/09 – 1990/06||B.S, Medical Technology, National Taiwan Univ., Taiwan|
|2016/03 – present||Associate Investigator, National Institute of Infectious Diseases nd Vaccinology, National Health Research Institutes, Taiwan|
|2008/03 – 2016/03||Assistant Investigator, Vaccine Research and Development Center, National Health Research Institutes, Taiwan|
|2005/01 – 2007/12||Research Associate, Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, USA|
|2002/01 – 2004/12||Postdoctoral Fellow, Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, USA|
|1995/09 – 1996/08||Research Assistant, Graduate Institutes of Clinical Medicine, National Taiwan University, Taipei, Taiwan|
|1992/07 – 1993/07||Research Assistant, Department of Medical Technology, Chang-Gung Medical College, Taiwan|
|1990/10 – 1992/05||Administrator, medical record department, 817 Army Hospital, Taiwan|
Honors & Awards
|2003 – 2005||Scholarship from the Gilbert F. Otto Young Investigator Fund, Johns Hopkins University, U.S.A.|
|2002 – 2003||Postdoctoral fellowship from Dept. Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, U.S.A|
|2001 – 2001||PhD Student Thesis Research Award, Institute of Life Sciences, National Defense Medical College, Taiwan|
|1999 – 1999||Travel Award from the Foundation for The Advancement of Outstanding Scholarship, Taiwan|
My interests focus on the interaction between host immune system and infectious viruses, particular in the fields of viral pathogenesis and vaccine R&D. I used genetic vaccine and recombinant viral vector to study how the host immunity was induced and modulated against virus infection, particular in measles virus (MV), Japanese encephalitis virus (JEV) and hepatitis C virus. In additional, I also investigated the protective mechanism of JEV infection, and the pathogenesis of MV persistence. My ongoing project is to develop a therapeutic cancer vaccine based on the knowledge of recombinant viral vector. SPECIAL FIELD Development of recombinant measles viral vector and biocompatible microparticle vaccine delivery system.
- Experienced in the evaluation of vaccine immunogenicity in animal models (mouse and rhesus macaque).
- Specialized in the R&D of vaccine delivery system, including a measles viral vector and microparticle formulated subunit vaccine
- R&D in vaccine against flavivirus viruses, including Japanese encephalitis virus and dengue virus.
- The host immunity required for the defense of invasive candidiasis.
Research Activities & Accomplishment
- I have conducted two vaccine monkey trials, including dengue EDIII subunit vaccine and EV71 inactivated virus vaccine and contributed to the future application of these vaccine candidates in human.
- I have developed a recombinant measles viral vector for vaccine and oncolytic tumor therapy.
- I have developed a biodegradable cationic microparticle for protein and DNA vaccine delivery.
- I have successfully established a mouse model for Candida alibicans colonization in guts and invasion relevant to clinical progression.
PATENTS 1. Cationic biodegradable polyceramic microparticles for vaccine delivery. (NHRI ITTC: 105004, submitted) MEMBERSHIP Member Association of Molecular and Cellular Biology, R. O. C. (1999) Member American Society for Virology (2007) Member American Association of Immunology (2007)
Research Grant Participation
- Development of a Candida mucosal/systemic infection mouse model to evaluate diagnostic biomarkers or therapeutic targets. MOST 104-2314-B-400-025- (1/3); 2015/8/1 to 2016/7/31
- Evaluation of the potency of the viral vector dengue vaccine: Using the interferon receptor gene knockout mouse as an animal model. MOST 103-2320-B-400-016-MY3; 2014/8/1 to 2017/7/31
- Development of a tetravalent dengue vaccine delivered by a measles viral vector. NSC 99-2320-B-400-004-MY3; 2010/8/1 to 2013/7/31.